Shareholder Bessemer Group Increased Facebook (FB) Position; Sio Capital Management Lowered Its Sage Therapeutics (Put) (SAGE) Stake by $1.84 Million as Share Value Declined

April 26, 2018 - By Vivian Park

Sage Therapeutics, Inc. (NASDAQ:SAGE) Logo

Sio Capital Management Llc decreased its stake in Sage Therapeutics Inc (Put) (SAGE) by 5.88% based on its latest 2017Q4 regulatory filing with the SEC. Sio Capital Management Llc sold 11,200 shares as the company’s stock declined 6.84% with the market. The institutional investor held 179,200 shares of the health care company at the end of 2017Q4, valued at $29.52 million, down from 190,400 at the end of the previous reported quarter. Sio Capital Management Llc who had been investing in Sage Therapeutics Inc (Put) for a number of months, seems to be less bullish one the $6.62 billion market cap company. The stock increased 3.05% or $4.28 during the last trading session, reaching $144.64. About 194,190 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 135.95% since April 26, 2017 and is uptrending. It has outperformed by 124.40% the S&P500.

Bessemer Group Inc increased its stake in Facebook Inc (FB) by 9.75% based on its latest 2017Q4 regulatory filing with the SEC. Bessemer Group Inc bought 4,789 shares as the company’s stock declined 14.10% with the market. The institutional investor held 53,916 shares of the technology company at the end of 2017Q4, valued at $9.52M, up from 49,127 at the end of the previous reported quarter. Bessemer Group Inc who had been investing in Facebook Inc for a number of months, seems to be bullish on the $509.57 billion market cap company. The stock increased 10.06% or $16.06 during the last trading session, reaching $175.75. About 64.07M shares traded or 78.09% up from the average. Facebook, Inc. (NASDAQ:FB) has risen 8.48% since April 26, 2017 and is uptrending. It has underperformed by 3.07% the S&P500.

Sio Capital Management Llc, which manages about $116.75 million and $177.32M US Long portfolio, upped its stake in Xencor Inc (NASDAQ:XNCR) by 76,881 shares to 109,981 shares, valued at $2.41 million in 2017Q4, according to the filing. It also increased its holding in Kura Oncology Inc by 116,296 shares in the quarter, for a total of 392,027 shares, and has risen its stake in Anthem Inc (NYSE:ANTM).

Since December 14, 2017, it had 0 buys, and 4 sales for $37.32 million activity. STARR KEVIN P had sold 59,000 shares worth $9.96 million on Tuesday, April 17. 60,000 shares valued at $9.57M were sold by Robichaud Albert on Thursday, December 14. PAUL STEVEN M sold 58,139 shares worth $10.00M.

Analysts await Sage Therapeutics, Inc. (NASDAQ:SAGE) to report earnings on May, 8. They expect $-1.85 EPS, down 21.71% or $0.33 from last year’s $-1.52 per share. After $-1.75 actual EPS reported by Sage Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 5.71% negative EPS growth.

Among 18 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 16 have Buy rating, 0 Sell and 2 Hold. Therefore 89% are positive. SAGE Therapeutics had 57 analyst reports since September 3, 2015 according to SRatingsIntel. Cowen & Co maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) on Thursday, November 9 with “Buy” rating. The company was maintained on Thursday, November 2 by Stifel Nicolaus. Canaccord Genuity maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) on Tuesday, September 12 with “Buy” rating. The firm earned “Buy” rating on Thursday, October 19 by SunTrust. Leerink Swann maintained the stock with “Buy” rating in Tuesday, September 12 report. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Buy” rating given on Thursday, August 3 by Cowen & Co. SunTrust maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) rating on Thursday, December 7. SunTrust has “Buy” rating and $178.0 target. The firm earned “Buy” rating on Tuesday, June 13 by Needham. Chardan Capital Markets initiated Sage Therapeutics, Inc. (NASDAQ:SAGE) on Tuesday, May 24 with “Sell” rating. The firm has “Buy” rating given on Monday, April 23 by BMO Capital Markets.

Investors sentiment increased to 1.49 in Q4 2017. Its up 0.28, from 1.21 in 2017Q3. It improved, as 27 investors sold SAGE shares while 56 reduced holdings. 63 funds opened positions while 61 raised stakes. 41.45 million shares or 7.53% more from 38.55 million shares in 2017Q3 were reported. Bailard stated it has 0.02% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Employees Retirement Association Of Colorado reported 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Ghost Tree Ltd Co reported 21,537 shares. Nuveen Asset Management Ltd Co holds 8,814 shares or 0.01% of its portfolio. Moreover, Barclays Public Limited has 0.03% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 204,330 shares. Baker Bros Advsrs LP holds 0.88% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 616,514 shares. Meeder Asset Mgmt, a Ohio-based fund reported 179 shares. Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 2,078 shares. The New York-based Alliancebernstein Lp has invested 0.07% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Metropolitan Life Insur New York reported 0.03% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Intl Group has invested 0.01% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Castleark Mngmt Ltd Llc invested in 0.14% or 28,495 shares. State Of Wisconsin Invest Board owns 38,000 shares for 0.02% of their portfolio. Keybank Association Oh reported 1,760 shares stake. Suffolk Cap Mgmt Limited Liability Com holds 63,176 shares.

Investors sentiment increased to 1.21 in Q4 2017. Its up 0.06, from 1.15 in 2017Q3. It improved, as 57 investors sold FB shares while 621 reduced holdings. 147 funds opened positions while 670 raised stakes. 1.61 billion shares or 1.26% less from 1.63 billion shares in 2017Q3 were reported. Raymond James Finance Services Inc reported 0.53% in Facebook, Inc. (NASDAQ:FB). 20,144 were reported by Provise Grp Ltd Company. Highland Mgmt Lc accumulated 61,073 shares. Kansas-based Cognios Capital Limited Liability Corporation has invested 1.59% in Facebook, Inc. (NASDAQ:FB). Koshinski Asset Management Inc has 17,902 shares. Earnest Prns Ltd Liability Co stated it has 1,087 shares or 0% of all its holdings. 29,077 are owned by Comerica Securities. Private Cap reported 2.54% of its portfolio in Facebook, Inc. (NASDAQ:FB). Veritable LP accumulated 70,371 shares or 0.25% of the stock. Cambridge Advisors holds 6,080 shares or 0.39% of its portfolio. Boston Private Wealth Limited Liability invested in 201,199 shares. Inverness Counsel Limited Company has invested 2.52% of its portfolio in Facebook, Inc. (NASDAQ:FB). Evergreen Cap Management Ltd Liability has 34,731 shares. Montrusco Bolton Invs Inc has invested 0.99% in Facebook, Inc. (NASDAQ:FB). Shell Asset Mgmt owns 193,370 shares for 0.68% of their portfolio.

Since December 7, 2017, it had 0 insider purchases, and 42 sales for $1.47 billion activity. The insider Zuckerberg Mark sold 145,000 shares worth $22.98 million. Schroepfer Michael Todd sold $6.64M worth of stock. On Monday, April 2 the insider Sandberg Sheryl sold $8.57M. Another trade for 16,000 shares valued at $2.83M was sold by Cox Christopher K. $221.33 million worth of Facebook, Inc. (NASDAQ:FB) was sold by Koum Jan on Thursday, February 15. $134,125 worth of Facebook, Inc. (NASDAQ:FB) was sold by Stretch Colin on Tuesday, December 12.

Bessemer Group Inc, which manages about $25.77 billion US Long portfolio, decreased its stake in Lab Corp Of Amer Hldgs New (NYSE:LH) by 61,433 shares to 1.08M shares, valued at $171.94 million in 2017Q4, according to the filing. It also reduced its holding in Stamps.Com Inc (NASDAQ:STMP) by 1,800 shares in the quarter, leaving it with 4,600 shares, and cut its stake in Msa Safety Inc (NYSE:MSA).

Facebook, Inc. (NASDAQ:FB) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>